title: Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men?
abstract: Yes. Quadrivalent human papillomavirus (qHPV) vaccine reduces rates of anal intraepithelial neoplasia (AIN) by 50% to 54%, and persistent anal infection by 59%, associated with the 4 types of HPV in the vaccine (6, 11, 16, and 18) in young men who have sex with men (MSM); it also reduces external genital lesions by 66%, and persistent HPV infection associated with the same 4 HPV types by 48 to 59% in all young men, heterosexual men, and MSM.
authors.affiliation: Valley Family Medicine Residency, Renton, WA, USA.
authors.forename: Johnny
authors.initials: J
authors.lastname: Shum
authors.affiliation: Valley Family Medicine Residency, Renton, WA, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Kelsberg
authors.affiliation: University of Washington Health Sciences Libraries, Seattle, WA, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Safranek
mesh_terms: D001004:Anus Diseases / Q000517:prevention & control; D001005:Anus Neoplasms / Q000517:prevention & control*; D002278:Carcinoma in Situ / Q000517:prevention & control*; D003218:Condylomata Acuminata / Q000517:prevention & control*; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines
chemical_list: D053918:Papillomavirus Vaccines